Pressure will mount on the rupee
Several macroeconomic parameters are signalling problems ahead. The current account deficit has been widening each month and could well finish the financial year at nearly 3% of the gross domestic product (GDP).

Speculators create value in pharma stocks
In the aftermath of software stocks running on a new high, multinational pharma stocks have begun a similar run. Most of the leading pharma stocks hit the circuit filter on Monday and climbed further on Tuesday.

Exit US-64, enter ICICI bonds
If you've been considering an exit from the Unit Trust of India's (UTI's) US-64, here's some food for thought. Assuming that the scheme will maintain its annual dividend of 20% and three possible repurchase prices five years down the line, it might make sense to continue being invested in the scheme.

  Telecom reforms
  Software exports
  The Index